BioLoomics Inc.
The University of Colorado Connection
BioLoomics was founded in 2019 by Doug Chapnik (alum, CU Boulder Biochemistry), a graduate of Xuedong Liu ’s laboratory (CU Boulder Biochemistry). BioLoomics is developing next-generation Antibody Drug Conjugates (ADCs) for safer, more effective cancer therapies.
Funding Status and Investment Opportunities
- Industry Applications: Health and Wellness, Biotech, Therapeutics
- Funding Stage: Seed A Round
- Contact for Investment Inquiries: Doug Chapnik , dougchapnick@bioloomics.com
In the News
- BioLoomics raises $8.7M in seed financing (2023)
- Boulder Valley bioscience sector experiencing bounceback (2020)
- Colorado university and lab ventures to be showcased at second annual Destination Startup (2020)
- Six CU Boulder startups clean up at Advanced Industries Accelerator competition, winning $1.5M in grants (2019)
Venture Partners Programs
Technology Development Funding
U.S. Defense Advanced Research Projects Agency (DARPA)
This page was last updated on Aug. 15, 2025. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor E-Newsletter
The Insider is Venture Partners at CU Boulder's monthly newsletter featuring the latest headlines, news, events, opportunities and emerging innovations from the university. We have several editions for our audiences.
Questions about investment opportunities?
Media Inquiries
For marketing and communication inquiries, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.